NCT06627608View on ClinicalTrials.gov

Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-Wide Cohort

Not yet recruitingOBSERVATIONAL

Enrollment

10,000

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Chronic Hepatitis B

All Listed Sponsors

lead

Chinese University of Hong Kong

OTHER

NCT06627608 - Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-Wide Cohort | Biotech Hunter | Biotech Hunter